Naveris Expands Commercial Availability of NavDx Test for HPV-Positive Anal Cancer, Enhancing MRD Detection

Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the expanded commercial availability of the NavDx ...

January 13, 2025 | Monday | News
QIAcuity Digital PCR Expands Capacity to 12 Targets Simultaneously with New Software Update and High Multiplex PCR Kit

  QIAcuity digital PCR now offers ability for simultaneous detection of up to 12 targets from one biological sample, a more than two-fold inc...

January 13, 2025 | Monday | News
Revvity Secures FDA Clearance for EUROIMMUN’s Groundbreaking Free Testosterone Test

-Revvity, Inc.  announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemilu...

January 13, 2025 | Monday | News
Rise Therapeutics Completes Dose Escalation for R-2487 and R-3750, Advancing to Dose Expansion in Clinical Trials

Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines,  announced that it has completed dose esc...

January 07, 2025 | Tuesday | News
Adcentrx Doses First Patient in Phase 1a/b Study of ADRX-0405 for Advanced Solid Tumors

 Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company advancing innovative protein conjugates for cancer and other life-thr...

January 07, 2025 | Tuesday | News
Fujirebio and Eisai Forge Partnership to Advance Blood-Based Diagnostics for Neurodegenerative Diseases

Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Minato-ku, Tokyo), a wholly-owned subsidiary of H.U. Group Holdings, Inc. (Cha...

December 26, 2024 | Thursday | News
Roche Secures CE Mark for cobas® Mass Spec Solution, Bringing Automated Clinical Mass Spectrometry to Routine Laboratories Worldwide

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it has received CE mark approval for its cobas® Mass Spec solution including the cobas® i 601 ana...

December 19, 2024 | Thursday | News
Sanofi and Teva’s Duvakitug Achieves Key Milestones in Phase 2b Study for Ulcerative Colitis and Crohn’s Disease

Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., announced that the RELIEVE UCCD phase 2b study met its primary endp...

December 18, 2024 | Wednesday | News
Roche Announces European Approval of Vabysmo® Prefilled Syringe for Treatment of Major Retinal Diseases

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Medicines Agency has approved Vabysmo® (faricimab) 6.0 mg single-dose prefilled syringe ...

December 16, 2024 | Monday | News
Shaping Biopharma Purification: Phenomenex’s Vision for 2025

Matt Boag, Biopharmaceutical Product Marketing Manager at Phenomenex, discusses the transformative innovations shaping plasmid DNA, mRNA, and peptide purif...

December 12, 2024 | Thursday | Opinion
OmniScience and INmune Bio Join Forces to Transform Global Alzheimer’s Trial Operations with GenAI-Powered Data Platform

OmniScience and INmune Bio announced a pioneering partnership to revolutionize operations for INmune Bio’s global Phase 2 Alzheimer&...

December 05, 2024 | Thursday | News
Gilead Sciences Partners with Tubulis to Develop Next-Generation Antibody-Drug Conjugate for Solid Tumors

Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis announced that they have entered into an exclusive option and license agreement to discover...

December 04, 2024 | Wednesday | News
Deepull Secures FDA Breakthrough Device Designation for Transformative Bloodstream Infection Test

deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification, announced that it has receive...

December 02, 2024 | Monday | News
Eli Lilly Announces Positive Phase 2 Results for Muvalaplin, Oral Treatment for Elevated Lp(a) Levels and Heart Disease Risk

Eli Lilly and Company (NYSE: LLY) announced positive Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhi...

November 19, 2024 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close